

Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/N4EAE3DEF2B3EN.html>

Date: July 2022

Pages: 130

Price: US\$ 2,000.00 (Single User License)

ID: N4EAE3DEF2B3EN

Abstracts

Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides an overview of the Neisseria meningitidis Infections (Infectious Disease) pipeline landscape.

Neisseria Meningitidis is a severe bacterial infection of the bloodstream and meninges (a thin lining covering the brain and spinal cord). Symptoms include fever, neck stiffness, joint pain, nausea, confusion and drowsiness. Risk factors include age, smoking, mucosal lesions, overcrowding, climatic conditions such as dry seasons or prolonged drought and dust storms and concomitant respiratory infections.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Neisseria meningitidis Infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Neisseria meningitidis Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The *Neisseria meningitidis* Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for *Neisseria meningitidis* Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 7, 5, 3, 15, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase 0, Preclinical and Discovery stages comprises 2, 1, 2 and 2 molecules, respectively.

Neisseria meningitidis Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of *Neisseria meningitidis* Infections (Infectious Disease).

The pipeline guide reviews pipeline therapeutics for *Neisseria meningitidis* Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in *Neisseria meningitidis*

Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Neisseria meningitidis Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Neisseria meningitidis Infections (Infectious Disease)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Neisseria meningitidis Infections (Infectious Disease).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Neisseria meningitidis Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and @Scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Neisseria meningitidis Infections - Overview

Neisseria meningitidis Infections - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Neisseria meningitidis Infections - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Neisseria meningitidis Infections - Companies Involved in Therapeutics Development

Neisseria meningitidis Infections - Drug Profiles

Neisseria meningitidis Infections - Dormant Projects

Neisseria meningitidis Infections - Discontinued Products

Neisseria meningitidis Infections - Product Development Milestones

Featured News & Press Releases

Jan 08, 2022: CanSinoBIO announces approval for its MCV4 product Menhycia in China

Sep 27, 2021: New research presented at IDWeek 2021 reinforces Sanofi's robust vaccines pipeline including MenQuadfi and commitment to advancing public health protection

Jul 12, 2021: Sanofi's meningococcal disease jab meets all endpoints in Phase III trial

Jan 15, 2021: Microsuper-biological tetravalent meningococcal conjugate vaccine formally submitted for IND application

Nov 23, 2020: European Commission approves MenQuadfi, the latest innovation in meningococcal (MenACWY) vaccination for individuals 12 months of age and older

Sep 17, 2020: Sanofi receives CHMP positive opinion for MenQuadfi intended for prophylaxis against invasive meningococcal disease

Jun 22, 2020: Pfizer announces start of Phase 3 Clinical Trial of MenABCWY

May 29, 2020: The European Medicines Agency has finalised its assessment of an application to extend the use of Trumenba for the prevention of invasive meningococcal disease

Aug 29, 2019: \$440 million funding boost for vital health and medical research for all

stages of life

Nov 28, 2018: NIHR supports world-first trial of new nose drop to fight meningitis

Jun 27, 2018: European approval for lower dose of GSK's Meningitis vaccine

Jun 18, 2018: New way to determine protection of Men B vaccine against different strains

Apr 23, 2018: Pfizer Granted FDA Breakthrough Therapy Designation for TRUMENBA (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Children Ages 1 to 9 Years

Mar 06, 2018: TRUMENBA (Meningococcal Group B Vaccine) Now Available In Canada

Feb 07, 2018: GSK's meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Neisseria meningitidis Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Neisseria meningitidis Infections - Pipeline by AIM Vaccine Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Alopexx Inc, 2022

Neisseria meningitidis Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Biological E Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Bioworld Technologies Sdn Bhd, 2022

Neisseria meningitidis Infections - Pipeline by CanSino Biologics Inc, 2022

Neisseria meningitidis Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Eubiologics Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by GSK plc, 2022

Neisseria meningitidis Infections - Pipeline by Hilleman Laboratories Pvt Ltd, 2022

Neisseria meningitidis Infections - Pipeline by ImmunoBiology Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Intravacc BV, 2022

Neisseria meningitidis Infections - Pipeline by Inventprise LLC, 2022

Neisseria meningitidis Infections - Pipeline by Johnson & Johnson, 2022

Neisseria meningitidis Infections - Pipeline by Lanzhou Institute of Biological Products Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Neoculi Pty Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Novo Medi Sciences Pvt Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Omvax Inc, 2022

Neisseria meningitidis Infections - Pipeline by Pfizer Inc, 2022

Neisseria meningitidis Infections - Pipeline by ReAlta Life Sciences Inc, 2022

Neisseria meningitidis Infections - Pipeline by Sanofi, 2022

Neisseria meningitidis Infections - Pipeline by Suzhou Weichao Biotechnology Co Ltd, 2022

Neisseria meningitidis Infections - Pipeline by Wellstat Vaccines LLC, 2022

Neisseria meningitidis Infections - Dormant Projects, 2022

Neisseria meningitidis Infections - Dormant Projects, 2022 (Contd..2)

Neisseria meningitidis Infections - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Neisseria meningitidis Infections, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Targets, 2022

Number of Products by Stage and Targets, 2022

Number of Products by Mechanism of Actions, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Neisseria Meningitidis Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/N4EAE3DEF2B3EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N4EAE3DEF2B3EN.html>